SAB Biotherapeutics (SABS) Secures FDA Fast Track for SAB-142 Diabetes Immunotherapy
SAB Biotherapeutics (SABS) secures FDA Fast Track designation for SAB-142, a Stage 3 type 1 diabetes immunotherapy. Topline Phase 2b data expected in 2H 2027.
Approvals
FDA and other regulatory approvals.
Mirum Pharmaceuticals Meets Phase 3 EXPAND Endpoints for LIVMARLI; sNDA Planned for 2027
American Express to Pay $350 Million Penalty Over Compliance Program Reviews
Vir Biotechnology and Astellas Gain FDA Fast Track for Prostate Cancer Therapy VIR-5500
Perspective Therapeutics Shares Jump 10% After FDA Fast Track for PSV359 Alpha Therapy
Regulatory Approval
American Battery Technology Co. Secures $100M Export License for Recycled Black Mass
American Battery Technology Company (ABAT) receives U.S. Commerce Dept approval to export $100M of recycled black mass, scaling its global battery mineral sales.
